ข่าวประชาสัมพันธ์ Lung Cancer+vandetanib

IEAT and AstraZeneca Proactively Conduct Lung Screenings, Visiting GC and SCG Plants for AI-Assisted X-Rays to Drive Early Detection

The Industrial Estate Authority of Thailand (IEAT) and AstraZeneca (Thailand) Co., Ltd. are moving forward with the Health and Well-being Enhancement Program for Workers in Industrial Estates. The program provides lung screenings using AI innovation for personnel at industrial estate sites, aiming to detect abnormalities at an early stage. The field activity also featured insights from actress Pornthip "Aey" Skidjai, who shared her personal experience. These efforts are aimed at promoting

21 เมษายน 2569 10:54 น.

NCC Donates THB 1 Million from "Run for Mom" to Support Breast Cancer Center at the Thai Red Cross Society — The organizer of the "12 August Half Marathon... 02 เม.ย.

CAPRELSA(TM) (vandetanib) Receives Positive CHMP Opinion in the European Union for Treating Advanced Medullary Thyroid Cancer

AstraZeneca today announced that the Marketing Authorisation Application for CAPRELSA (vandetanib) received a positive opinion from the Committee for Medicinal Products for... พ.ย. 54

Vandetanib Phase II Trial Shows Significant Improvement of Progression Free Survival in Patients With Advanced Papillary or Follicular Thyroid Cancer

- This press release has been made available on worldwide (excluding US) press communication media for the benefit of correspondents writing for the... ก.ย. 53

Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology

Data from the Phase III ZODIAC(1) study in advanced non-small cell lung cancer patients, with the investigational drug vandetanib, were... มิ.ย. 52

Fourth Phase III Study of Vandetanib (ZACTIMA(TM), ZD6474) in Patients With Advanced Lung Cancer

A Phase III international, parallel group, randomised, double-blind study of vandetanib in combination with pemetrexed for advanced non-small cell lung cancer (NSCLC) after failure of first line anti... ก.พ. 50